Cite
HARVARD Citation
Luo, X. et al. (n.d.). Comparison of 208‐week sequential therapy with telbivudine and entecavir in HBeAg‐positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg‐IFNα‐2a therapy: An open‐labelled, randomized, controlled, "real‐life" trial. Journal of viral hepatitis. pp. 36-42. [Online].